shroom-stocks

Novamind (NM.CN) is a company that addresses mental health. Utilizing a network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine. The company states they are…
Rollbacks Yesterday Core One Labs (COOL.C) announced an 8:1 share rollback to prepare itself for a Nasdaq listing. Today the company has 114,600,611 common shares outstanding, after the rollback,…
Multiple pivots Mind Cure (MCUR.C) began as a mushroom nootropic deal that has since shifted to ibogaine production and the development digital platforms. The company has been able to…
Last week Cybin (CYBN.NE) announced it was targetting alcoholism with its novel psychedelic compound CYB003. Another EG staffer wrote a piece last Monday outlining the details of the plan,…
Street cred MindMed (MMED.NEO) announced last fall it was applying to be listed on the Nasdaq Exchange. MindMed would be the first Canadian psychedelics company listed on a major…
+135k shares in a downturn, my man The psychedelics sector is down bad this week.   Just look at the psychedelics ETF PSYK.NE.   It’s not an alarm or…
Humming in Q1 I’ve had a rough year, but Revive (RVV.C) sure hasn’t.   With a portfolio based around psychedelics, cannabis, and diseases – this company has made 3…
Mydecine Innovations Group (MYCO.C) signed a non-binding letter of intent to acquire NeuroPharm, a Canadian-based healthcare company involved in the nascent shroom-space earlier this week. The all-share deal will…